UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant [X]

Filed I	y a Party	y other than the Registrant []	
Check	the appr	opriate box:	
[] [] [X] []	Confi Defini Defini	ninary Proxy Statement dential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) itive Proxy Statement itive Additional Materials ting Material under §240.14a-12	
		Cocrystal Pharma, Inc.	
		(Name of Registrant as Specified In Its Charter)	
		(Name of Person(s) Filing Proxy Statement, if other than the Registrant)	
Paym	ent of Fil	ing Fee (Check the appropriate box):	
[X]	No fee	e required.	
[]	Fee co	omputed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.	
	(1)	Title of each class of securities to which transaction applies:	
	(2)	Aggregate number of securities to which transaction applies:	
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):	
	(4)	Proposed maximum aggregate value of transaction:	
	(5)	Total fee paid:	
[]	Fee pa	Fee paid previously with preliminary materials.	
[]		box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the bus filing by registration statement number, or the Form or Schedule and the date of its filing.	
	(1)	Amount Previously Paid:	
	(2)	Form, Schedule or Registration Statement No.:	
	(3)	Filing Party:	
	(4)	Date Filed:	
conne		stal Pharma, Inc. (the "Company") is distributing the following announcement via email transmission to the stockholders of the Company as of April 20, 2021 in the annual meeting of stockholders of the Company to be held at 2:00 p.m. EST on June 16, 2021.	

Vote today, with instructions provided by your broker. Every stockholder vote is important. EVEN IF YOU SOLD YOUR SHARES.
 For assistance with voting your shares, please contact Cocrystal Pharma, Inc.'s proxy Okapi Partners at (877) 629-6356

Cocrystal Pharma, Inc. encourages all stockholders to vote with the board recommendations on ALL proposals in advance of the June 16th, 2021 virtual stockholder meeting.

Cocrystal Pharma, Inc. Reminds Stockholders to vote ahead of the 2021 Annual Meeting

Cocrystal Pharma, Inc's board of directors recommends stockholders vote "FOR" the proposal to approve an amendment to the Certificate of Incorporation of the Company.

The Charter Amendment requires the affirmative vote of at least a majority of the outstanding common stock entitled to vote

We understand your concern, however, the Board has no current plans to issue any additional shares of common stock following the effectiveness of the Charter Amendment.

Voting online or by telephone are the easiest ways to vote:

Vote Online (Highly Recommended): Follow the instructions provided by your broker, bank or other nominee on the Voting Instruction Form ("VIF"). This form was mailed to the address on record with your broker and also emailed if you elected electronic notification. You will need your voting control number which is included on the VIF to vote online.

Vote by Telephone: Follow the instructions provided by your broker, bank or other nominee on the VIF mailed (or emailed) to you. You will need your voting control number which is included on the VIF to vote via automated telephone service.

For assistance with voting your shares, please contact Cocrystal Pharma, Inc.'s proxy solicitor Okapi Partners at (877) 629-6356/ 212) 297 0720 (international)/info@okapipartners.com.